Navigation Links
Panacea Pharmaceuticals Announces the Availability of BC Detect(SM), a Serum- Based Diagnostic Test for Breast Cancer
Date:10/17/2007

novel agents for the treatment of cancer with liver cancer as the first therapeutic indication. The Company is exploring both naked anti-HAAH antibodies as well as HAAH antibodies conjugated to chemotherapeutic agents and toxins. PAN-622 is an all-human sequence anti- HAAH monoclonal antibody that has demonstrated excellent efficacy in animals, and is currently in development as a cancer therapeutic.

About Panacea Pharmaceuticals, Inc.

Panacea Pharmaceuticals, Inc. is a privately-held biopharmaceutical company focused on the development and commercialization of therapeutics and diagnostics for diseases with substantial, unmet clinical needs. The Company's product development strategy is based on novel therapeutic agents and approaches for cancer treatment, as well as acute and chronic neurodegenerative conditions, such as hypoxia-induced neurological insult, Parkinson's Disease, and Alzheimer's Disease. Panacea has an extensive patent portfolio covering its neurodegenerative and oncology technologies. Panacea Laboratories is a division of Panacea Pharmaceuticals, Inc.

More information about the Company is available at http://www.PanaceaPharma.com.

Except for historical information presented in this press release, matters discussed herein may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements are based on the opinions and estimates of management only as of the date of this release and are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance, or achievements expressed or implied by such statements. Factors that might cause such a difference include, but are not limited to, uncertainties related to our access to capital, the progress, costs, and results of any clinical trials undertaken by us, progress of our research a
'/>"/>

SOURCE Panacea Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...stCall/ -- Dendreon Corporation (Nasdaq: DNDN ) t...tration (FDA) provided written acknowledgement tha...ion (BLA) for PROVENGE® (sipuleucel-T) is a c...tion Drug User Fee Act (PDUFA) date of May 1, 2010...ded BLA. Dendreon is seeking licensure for PROVEN...
(Date:11/20/2009)...ently announced that a free webinar, “Roller...rticle Characterization”, will be presented ...tion of in situ particle characterization is demon...ies of roller compaction runs while varying raw ma... , (PRWEB) November 20, 2...
(Date:11/19/2009)...tCall/ -- Omeros Corporation (Nasdaq: OMER ) toda...ird quarter ended September 30, 2009. For the thre... a net loss of $3.9 million, or $1.34 per share, a... per share, for the same period in 2008. For the n...eported a net loss of $15.5 million, or $5.29 per ...
(Date:11/19/2009)...e-FirstCall/ -- Spherix Incorporated (Nasdaq: SPE...erapy, and a provider of technical and regulatory ...logy and pharmaceutical companies, today announced...olders. ,, At the meeting, shareholders of Sphe...owing members to the Board of Directors: ,, Do...
Breaking Biology Technology:Dendreon Receives FDA Acknowledgement of Complete Response 2Dendreon Receives FDA Acknowledgement of Complete Response 3Roller Compaction Process Optimization Using At-Line Particle Characterization 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Spherix Announces Results of Annual Shareholders Meeting 2Spherix Announces Results of Annual Shareholders Meeting 3Spherix Announces Results of Annual Shareholders Meeting 4
...Inc. (Nasdaq: CVTX ) announced today that it has ... Medicines Agency (EMEA) for ranolazine for,the tr...European Union (EU),member states. This approval f...for Medicinal Products for Human Use (CHMP) on Apr...urope as add-on therapy for the,symptomatic treatm...
... in Treatment of Heart Failure ...y 10 Bioheart, Inc.,(Nasdaq: BHRT ), a company c...logics that help monitor, diagnose and treat heart...ced it has secured worldwide,non-exclusive distrib...nitor, an interactive and simple-to-use at-home in...
...l/ -- Yongye Biotechnology,International, Inc. ("Y...),a leading distributor of plant and animal nutrie... it has engaged MSPC Certified Public,Accountants ...ditor., The Company has engaged MSPC Certified Pu...ve as the Company,s independent auditor effective,...
Other Biology Technology:CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina 2CV Therapeutics Receives European Marketing Authorization for Ranolazine for the Treatment of Patients With Chronic Angina 3Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients 2Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients 3Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients 4Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients 5Yongye Biotechnology International, Inc. Appoints New Independent Auditor 2
(Date:11/20/2009)...esearchers are invited to contribute their abstrac... WCO ECCEO10), the largest global meeting devoted... research and patient care. The Congress will be h...inning today, abstracts can be submitted online at...on deadline is February 4, 2010. , IOF and ESCEO...
(Date:11/20/2009)... , Toxic dust: Toxins in coal-tar-based sealcoa...ted house dust, according to a USGS study. PAHs ...ecules found in oil, coal and tar deposits, and ca...Hs are often found in house dust; however, the spe...ed. Researchers found that dust from indoor areas ...
(Date:11/20/2009)...urplus biomass from the production of flax shives,...flowered plant related to those which engulf field...is has been suggested by two studies carried out b...he journal Renewable and Sustainable Energy Revie...ntal point of view, the production of bioethanol f...
Breaking Biology News(10 mins):Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 3From toxic dust and algae to ill winds from Africa 2From toxic dust and algae to ill winds from Africa 3From toxic dust and algae to ill winds from Africa 4From toxic dust and algae to ill winds from Africa 5Flax and yellow flowers can produce bioethanol 2Wounded Warrior Project 28WWP 29 Seeks to Provide Mind Body and Spirit Healing for Combat Stress 50652 1Wounded Warrior Project 28WWP 29 Seeks to Provide Mind Body and Spirit Healing for Combat Stress 50652 2Pennsylvania DEP Lehigh Valley Berks County Air Quality Partnership Urge Public Transit Use 50648 1Pennsylvania DEP Lehigh Valley Berks County Air Quality Partnership Urge Public Transit Use 50648 2Extreme Heat Causes Major Health Problems for Older Adults 50644 1Extreme Heat Causes Major Health Problems for Older Adults 50644 2
...of photosynthesizing microbes in prehistoric rocks...pplied innovative techniques to previously unexami...on the "Slushball Earth" side of a decades-long sc...t. 29 Science Express. The lead author is Alison O...C College of Letters, Arts and Sciences. , Geologi...
...he longstanding challenges in the synthesis of pha...continuous regeneration of molecules called cofact...and environmentally friendly biocatalytic processe...y of Illinois at Urbana-Champaign and the Universi...d a microreactor that efficiently regenerates cofa...
...oming paper in the international, open-access jour...n yet between a newly identified virus and the ped.... Following their recent description of the corona...uggest this is one of the most frequently detected...infections (LRTIs). These infections are estimated...
Other Biology News:Study casts doubt on 'Snowball Earth' theory 2Microreactor efficiently regenerates cofactors for biocatalysis 2A novel virus for croup 2
...nes ,High Quality, Functionally-Validated, Ion Cha... having a critical role in nerve and muscle functi...NS and the heart. Drugs that modulate ion channels... as neuropathic pain, cardiac arrhythmia, hyperten...
Mouse Anti-Human TTC3 Monoclonal Antibody, Unconjugated, Clone 2D10 from Abnova Corporation
Mouse Anti-Human DENR Monoclonal Antibody, Unconjugated, Clone 1H3 from Abnova Corporation
Mouse Anti-Human CRKRS Monoclonal Antibody, Unconjugated, Clone 3C1 from Abnova Corporation
Biology Products: